AMT-116 ADC / Multitude Therap - LARVOL DELTA

AMT-116 in Patients with Solid Tumors (clinicaltrials.gov) - P1/2 | N=144 | Recruiting | Sponsor: Multitude Therapeutics Inc.

New P1/2 trial • Oncology • Solid Tumor

AMT-116-01: AMT-116 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Multitude Therapeutics Inc. | N=48 ➔ 80

Enrollment change • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. (ASCO 2024) - P1 | "AMT-116 is a first-in-class antibody-drug conjugate (ADC) targeting CD44v9, by conjugating a novel topoisomerase I inhibitor, belotecan derivative named KL610023 (Sichuan Kelun-Biotech) to a humanized anti-CD44v9 immunoglobulin G1 (IgG1) antibody via a hydrolysable linker with an average drug-to-antibody ratio of 7-8. These preliminary data indicate that AMT-116 is well tolerated at the first two dose levels in patients with heavily pretreated advanced solid tumors. Dose escalation is ongoing. Clinical trial information: NCT05725291."

Clinical • Metastases • P1 data • Anal Carcinoma • Cervical Cancer • Fatigue • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatocellular Cancer • Leukopenia • Oncology • Solid Tumor • Squamous Cell Carcinoma

AMT-116 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Multitude Therapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

AMT-116 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Multitude Therapeutics Inc.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor